Tbilisi

Running trials

• Recruiting

  Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer

  NCT07851025· Phase 3· Source

• Recruiting

  A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab

  NCT07391670· Phase 1· Source

• Recruiting

  A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

  NCT06996782· Phase 1/2· Source

• Recruiting

  Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

  NCT07044336· Phase 3· Source

• Recruiting

  A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

  NCT07069712· Phase 2· Source

• Recruiting

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

  NCT06868277· Phase 3· Source

• Active, not recruiting

  A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus

  NCT06700538· Phase 1/2· Source

• Active, not recruiting

  Volrustomig Priming Regimens Exploratory Phase II Platform Study

  NCT06448754· Phase 2· Source

• Recruiting

  AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

  NCT06219941· Phase 2· Source

• Active, not recruiting

  A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer

  NCT04931654· Phase 1/2· Source

• Active, not recruiting

  A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

  NCT04995523· Phase 1/2· Source

• Recruiting

  iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases

  NCT03549754· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer3 recruiting
• Gastric and esophageal cancer2 recruiting
• Liver and biliary tract cancer2 recruiting
• Chronic kidney disease1 recruiting
• Endometrial cancer1 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

  NCT07402915· Phase 1· Source

• Completed

  A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

  NCT05568095· Phase 3· Source

• Terminated

  Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC

  NCT04786964· Phase 3· Source